In the TCGA, CGGA, and REMBRANDT datasets, we demonstrated that the expression of IL-1β and IL-18 were significantly increased in grade IV gliomas, compared to those in WHO grade II and grade III gliomas (Figures 1A,D,G). The gene discussed is IL18; the disease is central nervous system cancer.